It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Induced pluripotent stem cells (iPSCs) can in principle differentiate into any cell of the body, and have revolutionized biomedical research and regenerative medicine. Unlike their human counterparts, mouse iPSCs (miPSCs) are reported to silence transposable elements and prevent transposable element-mediated mutagenesis. Here we apply short-read or Oxford Nanopore Technologies long-read genome sequencing to 38 bulk miPSC lines reprogrammed from 10 parental cell types, and 18 single-cell miPSC clones. While single nucleotide variants and structural variants restricted to miPSCs are rare, we find 83 de novo transposable element insertions, including examples intronic to Brca1 and Dmd. LINE-1 retrotransposons are profoundly hypomethylated in miPSCs, beyond other transposable elements and the genome overall, and harbor alternative protein-coding gene promoters. We show that treatment with the LINE-1 inhibitor lamivudine does not hinder reprogramming and efficiently blocks endogenous retrotransposition, as detected by long-read genome sequencing. These experiments reveal the complete spectrum and potential significance of mutations acquired by miPSCs.
Retrotransposons are mobile genetic elements normally repressed by DNA methylation in differentiated cells. Here, the authors show that DNA hypomethylation in mouse induced pluripotent stem cells allows retrotransposons to jump, but this can be blocked with a reverse transcriptase inhibitor.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Mater Research Institute - University of Queensland, Woolloongabba, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
2 Monash University, Department of Anatomy & Developmental Biology, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash Biomedicine Discovery Institute, Development and Stem Cells Program, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Australian Regenerative Medicine Institute, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
3 Mater Research Institute - University of Queensland, Woolloongabba, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); GENYO. Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research, PTS, Granada, Spain (GRID:grid.418805.0) (ISNI:0000 0004 0500 8423)
4 The University of Western Australia, Australian Research Council Centre of Excellence in Plant Energy Biology, School of Molecular Sciences, Perth, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910); Harry Perkins Institute of Medical Research, Perth, Australia (GRID:grid.431595.f) (ISNI:0000 0004 0469 0045)
5 Monash University, Department of Anatomy & Developmental Biology, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash Biomedicine Discovery Institute, Development and Stem Cells Program, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Australian Regenerative Medicine Institute, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); The University of Adelaide, Adelaide Centre for Epigenetics and The South Australian Immunogenomics Cancer Institute, Faculty of Health and Medical Sciences, Adelaide, Australia (GRID:grid.1010.0) (ISNI:0000 0004 1936 7304)
6 Mater Research Institute - University of Queensland, Woolloongabba, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); University of Queensland, Queensland Brain Institute, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)